http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( So Ri Kim ),( Yong Chul Lee ),( Dong Im Kim ),( Yang Keun Rhee ),( Heung Bum Lee ),( Seoung Ju Park ),( Chi Ryang Chung ),( Seung Yong Park ),( Mi Ran Kang ) 대한결핵 및 호흡기학회 2012 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.114 No.-
Oxidative stress is well known to be implicated in the development of asthma. The mitochondrial respiratory chain is a major site of intracellular reactive oxygen species (ROS) generation and, at the same time, an important target for the damaging effects of ROS. Mito-Tempo is a specific mitochondrial ROS inhibitor and it is known to be associated with opening of mi-tochondrial permeability transition pore and inhibition of cell necroptosis or apoptosis. However, there is little information on the protective effects of Mito-Tempo on the inflammatory airway disorders including bronchial asthma and its acute exacerbation. We investigate the effects of Mito-tempo on the allergic airway inflammation and hyperresponsiveness using the mice sensitized with OVA and LPS and then challenged with OVA (OVALPS-OVA mice). The OVALPS-OVA mice showed the typical features of neutrophilic asthma; increased airway inflammatory cells, the pathologic changes, the increased levels of Th2 cytokines in lungs of OVALPS-OVA mice, increased mitochondrial ROS generation, and increased bronchial hyperresponsiveness. Interestingly, we found that in OVALPS-OVA mice, Mito-Tempo, a novel mitochondrial targeting agent significantly reduced the increases in inflammatory cytokines, mitochondrial ROS generation, airway inflammation, and bron-chial hyperresponsiveness. These findings indicate that mitochondrial dysfunction including oxidative damage may be im-plicated in the pathogenesis of bronchial asthma and provide the therapeutic potential of a mitochondrial targeting agent, Mito-Tempo, for bronchial asthma.
Stage-dependent gene expression profiles during natural killer cell development
Kang, Hyung-Sik,Kim, Eun-Mi,Lee, Sanggyu,Yoon, Suk-Ran,Kawamura, Toshihiko,Lee, Young-Cheol,Kim, Sangsoo,Myung, Pyung-Keun,Wang, San Ming,Choi, Inpyo Elsevier 2005 Genomics Vol.86 No.5
<P><B>Abstract</B></P><P>Natural killer (NK) cells develop from hematopoietic stem cells (HSCs) in the bone marrow. To understand the molecular regulation of NK cell development, serial analysis of gene expression (SAGE) was applied to HSCs, NK precursor (pNK) cells, and mature NK cells (mNK) cultured without or with OP9 stromal cells. From 170,464 total individual tags from four SAGE libraries, 35,385 unique genes were identified. A set of genes was expressed in a stage-specific manner: 15 genes in HSCs, 30 genes in pNK cells, and 27 genes in mNK cells. Among them, lipoprotein lipase induced NK cell maturation and cytotoxic activity. Identification of genome-wide profiles of gene expression in different stages of NK cell development affords us a fundamental basis for defining the molecular network during NK cell development.</P>
Antioxidant Activity of Limonene Perilla and Perilla Cultivar Using Different Solvents
Mi Ran Jeon(전미란),Ji Hye Yoo(유지혜),Jae Hoo Choi(최재후),Chang Heum Kim(김창흠),Byeong Ju Kang(강병주),Jae Geun Lee(이재근),Nam Jun Kim(김남준),Su Jin Yang(양수진),Jung Dae Lim(임정대),Seon Kang Choi(최선강),Chang Yeon Yu(유창연) 한국약용작물학회 2016 한국약용작물학회 학술대회논문집 Vol.2016 No.1
Prevalence of Oral Microbes in the Saliva of Oncological Patients
Mi-Sun Kang,Jong-Suk Oh,Hyeoung-Joon Kim,Hee-Nam Kim,Il-Kwon Lee,Hong-Ran Choi,Ok-Joon Kim,Young-Jong Ko,Won-Bong Lim,Hong-Ju Park,Min-Gi Yu,Kyung-Yi Chung,Seon-Mi Kim,Hoi-Soon Lim 대한미생물학회 2009 Journal of Bacteriology and Virology Vol.39 No.4
RFLP Analysis of cag7 Gene of Helicobacter pylori
Kang, Hyung-Lyun,Park, Jeong-Uck,Choe, Mi-Young,Kim, Kyung-Mi,Kim, Do-Su,Kwan, Young-Chul,Park, Seung-Gyu,Hwang, Hyang-Ran,Song, Jae-Young,Baik, Seung-Chul,Lee, Woo-Kon,Youn, Hee-Shang,Cho, Myung-Je The Korean Society for Microbiology 2004 Journal of Bacteriology and Virology Vol.34 No.3
The cag7 gene of Korean H. pylori strains was analyzed by RFLP to develop a discriminatory tool for genotyping clinical isolates. For this study, a total of 82 H. pylori strains were isolated from the patients; 27 strains from the patients with chronic gastritis, 26 from duodenal ulcer, and 29 from gastric cancer. Genomic DNA was isolated and subjected to PCR targeting entire ORF or the repeat regions I and II of cag7 gene. PCR products from entire ORF or repeat region I of cag7 gene were divided into two types. However, there was no difference in the length of PCR products from the repeat region II. By the PCR genotyping of the entire cag7 gene, genotypes A and B were established, which showed approximately 5,100 and 5,500 bp PCR products, respectively. The repeat region I showed approximately 600 or 1,000 bp DNA fragments by PCR. The length of cag7 gene was determined by the size variation in the repeat region I. In addition, RFLP analysis of the PCR products of cag7 gene showed 11 subtypes, based on the major bands. These findings illustrate that the genetic diversity of the repeat region I would serve a reliable target for the genotyping of the cag 7 gene.
Kang, Woo Youl,Seong, Sook Jin,Ohk, Boram,Gwon, Mi-Ri,Kim, Bo Kyung,La, Sookie,Kim, Hyun-Ju,Cho, Seungil,Yoon, Young-Ran,Yang, Dong Heon,Lee, Hae Won Dove Medical Press 2018 Drug design, development and therapy Vol.12 No.-
<P><B>Purpose</B></P><P>A new fixed-dose combination (FDC) formulation of telmisartan 80 mg and S-amlodipine 5 mg (CKD-828) has been developed to increase convenience (as only one tablet is required per day) and improve treatment compliance.</P><P><B>Methods</B></P><P>The pharmacokinetic characteristics and tolerability of an FDC of telmisartan and S-amlodipine were compared to those after coadministration of the individual agents in this randomized, open-label, single-dose, two-way, four-period, crossover study. To analyze the telmisartan and S-amlodipine plasma concentrations using a validated liquid chromatography–tandem mass spectrometry method, serial blood samples were collected up to 48 hours post-dose for telmisartan and 144 hours post-dose for S-amlodipine, in each period.</P><P><B>Results</B></P><P>Forty-eight healthy subjects were enrolled, and 43 completed the study. The mean peak plasma concentration (C<SUB>max</SUB>) and the area under the plasma concentration–time curve from time 0 to the last measurement (AUC<SUB>0–t</SUB>) values of telmisartan were 522.29 ng/mL and 2,475.16 ng·h/mL for the FDC, and 540.45 ng/mL and 2,559.57 ng·h/mL for the individual agents concomitantly administered, respectively. The mean C<SUB>max</SUB> and AUC<SUB>0–t</SUB> values of S-amlodipine were 2.71 ng/mL and 130.69 ng·h/mL for the FDC, and 2.74 ng/mL and 129.81 ng·h/mL for the individual agents concomitantly administered, respectively. The geometric mean ratio (GMR) and 90% confidence interval (CI) for the telmisartan C<SUB>max</SUB> and AUC<SUB>0–t</SUB> (FDC of telmisartan and S-amlodipine/concomitant administration) were 0.8509 (0.7353–0.9846) and 0.9431 (0.8698–1.0226), respectively. The GMR and 90% CI for the S-amlodipine C<SUB>max</SUB> and AUC<SUB>0–t</SUB> (FDC/concomitant administration) were 0.9829 (0.9143–1.0567) and 0.9632 (0.8798–1.0546), respectively. As the intrasubject variability of the C<SUB>max</SUB> for telmisartan administered individually was 42.94%, all 90% CIs of the GMRs fell within the predetermined acceptance range. Both treatments were well tolerated in this study.</P><P><B>Conclusion</B></P><P>CKD-828 FDC tablets were shown to be bioequivalent to coadministration of the individual agents with the respective strength, in healthy subjects under fasting conditions. There was no significant difference in safety profile between the two treatments.</P>
Kang, Jum-Ran,Lee, Mi Jin,Park, Sun Hye Elsevier 2017 COMPUTERS & MATHEMATICS WITH APPLICATIONS - Vol.74 No.6
<P><B>Abstract</B></P> <P>A viscoelastic problem with Balakrishnan–Taylordamping and time-varying delay of the form [FORMULA OMISSION] is considered. We prove a general stability result for the equation without the condition <SUB> μ 2 </SUB> > 0 by establishing some Lyapunov functionals which are equivalent to the energy of the equation instead of multiplier technique and using some properties of convex functions.</P>
Kang, Chan Woo,Jang, Kang Won,Sohn, Jinyoung,Kim, Sung-Moo,Pyo, Kyoung-Ho,Kim, Hwan,Yun, Mi Ran,Kang, Han Na,Kim, Hye Ryun,Lim, Sun Min,Moon, Yong Wha,Paik, Soonmyung,Kim, Dae Joon,Kim, Joo Hang,Cho, American Association for Cancer Research 2015 Molecular Cancer Therapeutics Vol.14 No.10
<P><I>RET</I> rearrangement is a newly identified oncogenic mutation in lung adenocarcinoma (LADC). Activity of dovitinib (TKI258), a potent inhibitor of FGFR, VEGFR, and PDGFR, in <I>RET</I>-rearranged LADC has not been reported. The aims of the study are to explore antitumor effects and mechanisms of acquired resistance of dovitinib in <I>RET</I>-rearranged LADC. Using structural modeling and <I>in vitro</I> analysis, we demonstrated that dovitinib induced cell-cycle arrest at G<SUB>0</SUB>–G<SUB>1</SUB> phase and apoptosis by selective inhibition of RET kinase activity and ERK1/2 signaling in <I>RET</I>-rearranged LC-2/ad cells. Strong antitumor effect of dovitinib was observed in an LC-2/ad tumor xenograft model. To identify the acquired resistance mechanisms to dovitinib, LC-2/ad cells were exposed to increasing concentrations of dovitinib to generate LC-2/ad DR cells. Gene-set enrichment analysis of gene expression and phosphor-kinase revealed that Src, a central gene in focal adhesion, was activated in LC-2/ad DR cells. Saracatinib, an src kinase inhibitor, suppressed ERK1/2 phosphorylation and growth of LC-2/ad DR cells. Taken together, these findings suggest that dovitinib can be a potential therapeutic option for <I>RET</I>-rearranged LADC, in which acquired resistance to dovitinib can be overcome by targeting Src. <I>Mol Cancer Ther; 14(10); 2238–48. ©2015 AACR</I>.</P>